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Abstract: The study of the ovarian proteomic profile represents a new frontier in ovarian 
cancer research, since this approach is able to enlighten the wide variety of post-translational 
events (such as glycosylation and phosphorylation). Due to the possibility of analyzing 
thousands of proteins, which could be simultaneously altered, comparative proteomics  
represent a promising model of possible biomarker discovery for ovarian cancer detection 
and monitoring. Moreover, defining signaling pathways in ovarian cancer cells through 
proteomic analysis offers the opportunity to design novel drugs and to optimize the use of 
molecularly targeted agents against crucial and biologically active pathways. Proteomic 
techniques provide more information about different histological types of ovarian  
cancer, cell growth and progression, genes related to tumor microenvironment and specific 
molecular targets predictive of response to chemotherapy than sequencing or microarrays. 
Estimates of specificity with proteomics are less consistent, but suggest a new role for 
combinations of biomarkers in early ovarian cancer diagnosis, such as the OVA1 test.  
Finally, the definition of the proteomic profiles in ovarian cancer would be accurate and  
effective in identifying which pathways are differentially altered, defining the most  
effective therapeutic regimen and eventually improving health outcomes. 
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1. Introduction 
Ovarian cancer represents one of the four main gynecological cancers, counting worldwide about 
225,000 new cancer cases diagnosed in 2008 (3.7% of all female cancers) and about 140,000 deaths 
(4.2% of all deaths in women) [1]. According to the American Cancer Society, in 2012, ovarian cancer 
was expected to account for 3% (22,280) of all new cases and 6% (15,500) of all female cancer deaths 
in the United States. The proportion of ovarian cancer among gynecological cancers is increasing;  
on the other hand, survival for ovarian cancer is the poorest of all gynecological cancer sites, with a 
five-year relative survival rates of 44% for all stages [2]. The main reasons for this poor survival are 
the lack of early detection strategies and an unfavorable anatomical situation. Thus, the vast majority 
of ovarian cancer is diagnosed at an advanced stage, and therapy for this pathology is very complex. 
Reduction in mortality rates could be gained from progresses in surgery and medical treatments and 
finding the correct role of an organized screening program. A major impact on the mortality from 
ovarian cancer and increases in survival rates could be gained translating recent insights at the 
molecular and cellular level to improve early detection and to personalize treatment strategies. 
Proteomic technology has emerged in the last decade as a powerful tool to explain the molecular 
mechanisms of malignant cells and tumor microenvironment in patients with cancer. Proteomics has 
given useful insight into the perturbations of signaling pathways within tumor cells, allowing one to 
find new targets for drug action, possible diagnostic markers and prognostic indicators of outcome and 
response to therapy [3,4]. The proteome represents all the possible gene products of a cell. Any protein 
may exist in multiple forms that vary within a particular cell or in different cells, because of  
modifications derived from translational, post-translational, regulatory and degradative processes that 
affect protein structure, localization, function and turnover. Proteomic techniques characterize all 
proteins in a biological system, including complicated features, like isoforms, modifications, 
interactions and functional structures. Particularly in cancer biomarker discovery, two-dimensional gel  
electrophoresis, mass spectrometry (MS) and protein microarrays, in conjunction with advanced  
bioinformatics, have become useful devices to identify proteins. 
This review summarizes the most frequent genetic pathways of sporadic and hereditary ovarian 
cancer, focusing on proteomic strategies aimed at identifying early diagnostic biomarkers, prognostic 
indicators of outcome and response to therapy and possible targets for drug action. 
2. Genetic Pathways of Sporadic Ovarian Cancer 
Ovarian cancer represents a heterogeneous disorder with different biology and behavior at the  
clinical, cellular and molecular levels. The normal ovary tissue is characterized by several distinct 
components. About 10% of ovarian cancers develop from germ cells or granulosa-theca cells, while 
more than 90% of ovarian cancers has an epithelial origin and arises from cells that cover the ovary. 
However, cancers with similar histology can also arise from the lining of the fallopian tube, deposits of 
endometriosis or the surface of the peritoneal cavity [5]. Epithelial ovarian cancer is divided into four 
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main histotypes, with a differentiation similar to the normal cells that line the fallopian tube (serous), 
endometrium (endometrioid), endocervix (mucinous) and vagina (clear cell). At a molecular level, the 
gene expression profiles of different ovarian cancer histotypes correlate with their morphological 
counterparts in normal tissues [6]. Particularly, histotypes correlate with the abnormal re-expression  
of homeobox (Hox) genes that are normally only expressed during gynecological organogenesis.  
Respectively, HOXA9 is expressed in the fallopian tube and serous ovarian cancer, HOXA10 in uterus 
and endometrioid cancer and HOXA11 in lower uterine segment and cervix and mucinous cancers [7]. 
On this basis, the classic theory regarding the role of the ovarian surface epithelium in ovarian cancer 
pathogenesis has been recently reconsidered. A novel hypothesis supports the direct involvement of 
the distal fallopian tube in the development of serous carcinomas and ectopic endometrium in  
endometrioid and clear cell carcinomas [8]. 
Protein expression analysis has been widely introduced in order to identify a signature that may 
characterize each distinct histotype. Apart from pathogenesis of different histotypes, the common  
genetic pathway of sporadic ovarian cancer is based on high genetic instability as a result of the  
activation or inactivation of specific genes. Activation of genes occurs through amplification, mutation 
and hypomethylation, whereas genetic inactivation results from deletion of large chromosomal  
regions, loss of heterozygosity at specific loci, mutations and promoter methylation (Figure 1).  
Figure 1. Several genetic alterations cause of high genetic instability in ovarian cancer. 
 
Within this wide genetic panel, a total of 16 tumor suppressor genes, a total of 15 oncogenes and 
three imprinted tumor suppressor genes can be identified (Table 1) [5,9]. Notably, the function of  
imprinted tumor suppressor genes can be lost in a single step, since only one allele is expressed in each 
cell, due to the inheritance of a silent maternal or paternal allele. Of the 16 candidate tumor suppressor 
genes identified to date, three are imprinted genes.  
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Table 1. Wide genetic panel involved in ovarian cancer pathogenesis. 
Tumor suppressor genes Oncogenes Imprinted tumor suppressor genes 
ARHI, RASSF1A, DLEC1, SPARC, 
DAB2, PLAG1, RPS6KA2, PTEN, 
OPCML, BRCA2, ARL11, WWOX, 
TP53, DPH1, BRCA1, PEG3 
RAB25, EVI1, EIF5A2, PRKCI, 
PIK3CA, MYC, EGFR, NOTCH3, 
KRAS, ERBB2, PIK3R1, CCNE1, 
AKT2, AURKA 
ARHI, PLAGL1, PEG3 
On the basis of the genetic profile, ovarian cancer can be divided in two different groups. Type I 
ovarian cancers include low-grade and borderline serous cancers, endometrioid, mucinous and clear-cell 
cancers. This group has more frequent PTEN, PI3K catalytic subunit-α (PIK3CA), KRAS, BRAF and  
b-catenin (CTNNB1) mutations, along with genomic stability and TP53 mutations in only a small  
fraction of cases. Type II ovarian cancers include high-grade serous carcinomas, mixed malignant 
mesodermal tumors, carcinosarcomas and undifferentiated cancers. These tumors have TP53  
mutations in up to 80% of cases, along with marked genomic instability and arise more frequently 
from the fallopian tubes and the peritoneum and in BRCA1 and BRCA2 mutation carriers [10].  
Interestingly, mutated TP53 has been observed in microscopic ovarian cancers found in oophorectomy 
specimens resected prophylactically from BRCA1 or BRCA2 mutation carriers, suggesting an early role 
of TP53 in hereditary disease. Alteration of TP53 function is one of the most frequent genetic  
abnormalities in ovarian cancer and is observed in 60%–80% of both sporadic and familial tumors. 
Overexpression of this tumor suppressor gene is seen in approximately 4% of preinvasive borderline 
tumors, 10%–20% of early cancers and 40%–60% of advanced cancers and correlates with metastatic  
potential. Moreover, TP53 mutation has been associated with resistance to platinum-based therapy in 
some studies and a short-term survival benefit [11].  
In ovarian cancer pathogenesis, the sequence of events includes the activation of several signaling 
pathways, which consist of several molecules intervening in cancer cell metabolism, proliferation,  
differentiation, movement and apoptosis. According to the literature, the signaling pathways involved 
in ovarian cancer pathogenesis are the following: the lysophosphatidic acid (LPA) pathway involved in 
90% of cases, the phosphatidylinositol 3-kinases (PI3K) pathway involved in 70% of cases, the  
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) pathway involved in more than 
50% of cases, the mitogen-activated protein kinase (MAPK) pathway involved in less than 50% of 
cases, the proto-oncogene tyrosine-protein kinase Src pathway, the Müllerian Inhibitory substance  
receptor pathway, the ErbB activation pathway involved in approximately 25% of cases, the epidermal 
growth factor (EGF) and vascular endothelial growth factor (VEGF) pathways, the endoplasmic  
reticulum (ER) beta pathways, the activator of transcription 3 (Jak-STAT 3) pathway, the  
Interleukin-6/Interleukin-6 receptor (IL-6/IL-6R) or the Janus Kinase 2 signal transducer pathways  
(Figure 2) [5,12]. The knowledge of a proteomic signature in ovarian cancer permits one to develop  
inhibitors of the molecules that are most frequently activated or overexpressed in ovarian cancers. 
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Figure 2. Signaling pathways in ovarian cancer pathogenesis. * Lysophosphatidic acid;  
** Receptor tyrosine kinases. 
 
3. BRCA-Related Ovarian Cancer 
The most important risk factor for ovarian cancer still remains a family history of breast or ovarian 
cancer. Up to 10% of ovarian cancer patients may have inherited a germline mutation that places them 
at increased risk for the disease. Mutations in the breast and ovarian cancer-susceptibility genes, 
BRCA1 and BRCA2, confer an increased lifetime risk of ovarian cancer. However, BRCA mutations do 
not account for the entire range of hereditary ovarian cancer syndromes. Other hereditary epithelial 
ovarian cancers are attributed to Lynch syndrome. Lynch syndrome is an autosomal dominant  
disorder, which predisposes to colorectal, endometrial, ovarian, gastric, small bowel,  
biliary/pancreatic, urothelial, skin and central nervous system cancers. The cumulative risk of ovarian 
cancer is estimated to be 8%–10%, with an average age of onset of 42 years [13]. Moreover, other 
genes often associated with rare cancer syndromes, such as TP53 and PTEN or CHEK2 and PALB2, 
confer a low to moderate risk for breast and ovarian cancer [14,15]. Recent technological advances 
have aided in the recognition of additional tumor suppressor genes potentially associated with hereditary 
breast and gynecologic cancer, such as RAD51 and BARD1 [16]. To date, at least 16 genes have been 
associated with hereditary ovarian cancer, mostly involved in the FA-BRCA pathway and the mismatch 
repair system. However, many families with suspicious pedigrees do not have a specific mutation 
identified through clinical testing, due to a currently undetectable BRCA1/2 mutation or a mutation in 
another susceptibility gene.  
Inheritance of DNA repair defects contributes to as many as 10%–15% of ovarian cancers. About 
90% of hereditary ovarian cancer derives from germline mutations in BRCA 1/2 genes. Women who 
have inherited genetic mutations have substantially increased risk of ovarian cancer, with a lifetime 
risk that varies with the genetic defect (for BRCA1, 30%–60%, for BRCA2, 15%–30% and for 
hereditary non-polyposis colon cancer, 7%) [17]. Particularly, BRCA-related ovarian cancers have 
characteristic behaviors. They are more frequently multifocal, with genetically distinct clones 
involving multiple sites and progress faster. These kinds of tumors are more sensitive to platinum-based 
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chemotherapy and poly(ADP-ribose) polymerase (PARP) inhibitors, which are particularly effective in the 
presence of defects in homologous recombination repair. However, germline mutation in BRCA1/2 genes 
can be involved even in the pathogenesis of BRCA1-like and BRCA2-like sporadic ovarian cancer [9].  
4. Proteomic Techniques  
4.1. Two-Dimensional Gel Electrophoresis (2DE) 
Traditionally, proteomic analyses have been performed using two-dimensional gel electrophoresis 
(2DE), which separates proteins according to two distinct protein characteristics, size and charge. The 
introduction of immobilized pH gradients and advanced bioinformatic approaches have recently  
improved the reproducibility and comparability of this technique [18]. In several studies, 2DE has 
been able to detect differences between normal and cancer sample proteomes [19].  
The analysis of the proteome started out with techniques based on 2DE and then extended with  
liquid chromatography–mass spectrometry (LC–MS)-based techniques. However, despite the rapid 
advance of MS-based proteomics, 2DE still plays a crucial role in several fields of protein and  
molecular biology. There is an important niche for 2D gel-based proteomics, which complete  
traditional LC-MS techniques, in the areas of protein identification from organisms with no or  
incomplete genome sequences available, alternative detection methods for modification of specific 
proteomics and identification of protein isoforms and modified proteins [20].  
4.2. Mass Spectrometry (MS) 
Mass spectrometry (MS) provides a snapshot of a proteome in time and space, determining the  
precise mass and charge (m/z) of proteins and, thus, identifying the actual precursor proteins or protein  
profiles. In recent years, MS instruments have been greatly modified and improved, becoming  
sensitive to the picomole to femtomole range required for the detection of oligonucleotides, small  
polar molecules, peptides, proteins and post-translationally modified proteins, such as glycoproteins 
and phosphoprotein [21]. Mass spectrometers are composed of an ion source, a mass analyzer and an 
ion detector. Different combinations of ionization sources (such as MALDI and ESI), mass analyzers 
(such as time-of-flight (TOF), quadrupole and ion traps) and fragmentation methods (such as CID  
(collision-induced dissociation), ETD (electron-transfer dissociation) and ECD (electron-capture  
dissociation)) can be used. 
Although 2DE is still used in several proteome studies, the shotgun mass spectrometry  
(shotgun-MS) has been widely introduced in recent years. A shotgun-MS strategy consists in the  
separation of peptides produced from protein digestion in complex mixtures followed by tandem mass 
spectrometry (MS/MS) analysis. Traditional shotgun proteomics is a useful tool for the analysis and 
identification of proteins and their variations in biological samples with a non-targeted approach.  
Biological samples are often heterogeneous and contain several different molecules; thus, methods 
of separation are often necessary to select the target to analyze from the other molecules in the sample. 
Gas (GC) or liquid chromatography (LC) are common methods of pre-MS separation used when  
analyzing complex gas or liquid samples. High performance liquid chromatography (HPLC) is the 
most common separation method to study biological samples by MS or MS/MS (termed LC-MS or 
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LC-MS/MS, respectively). Traditionally, the first step is sample lysis and protein extraction from the 
cells, tissues or body fluids, followed by digestion into peptides. This process generates thousands of 
peptides, which can be pre-fractionated according to their physicochemical properties (such as charge 
or isoelectric point) or enriched by different means (for example, affinity resins or specific antibodies). 
These pre-fractionated or enriched samples are then analyzed one-by-one by reversed-phase liquid 
chromatography coupled to mass spectrometry (LC–MS), in which selected peptides are fragmented 
by tandem mass spectrometry (MS/MS). MS and MS/MS are connected to computer software that  
analyzes the detected ions by their individual m/z and relative abundance. These ions can then be  
processed through databases to identify the corresponding peptide sequences [22,23].  
Among the MS-based proteomics approaches, matrix assisted laser desorption/ionization mass 
spectrometry (MALDI MS) and surface enhanced laser desorption/ionization mass spectrometry 
(SELDI MS) have been employed for large scale polypeptide profiling in clinical proteomics [19]. 
Proteomic profiling with MALDI and SELDI MS has been used to investigate the spatio-chemical 
make-up of a tissue, identifying peptides and proteins that are specific to the different cell types that 
characterize a tumor. Particularly, these techniques have been applied to identify new candidate  
ovarian cancer biomarkers [24]. 
MS-based proteomics is a universally used technique for analyzing complex protein samples. To 
visualize the spatial distribution of specific molecules in biological systems, an increasing number of 
groups are looking to combine the sensitivity and specificity of mass spectrometry with imaging  
capabilities. This involved both of the macromolecular ionization techniques, MALDI and ESI and 
provided a foundation for secondary ion mass spectrometry (SIMS) imaging. Since MALDI provides 
proteomics information and SIMS that of lipids and other surface active species, several groups now 
use the complementary information provided by SIMS and MALDI to obtain proteomics, lipid and 
vitamin distributions within the same tissue section [25]. However, MALDI-mass spectrometry  
Imaging (MALDI-MSI) has not yet been used to map the transcriptome, which includes microRNA 
and other RNA-related molecules, and represents now a wide area of clinical research. To investigate 
this important topic, targeted mass spectrometric imaging (Tag-Mass MSI) has been developed.  
Particularly, targeted MSI may be used to complement MALDI-MSI for clinical research. For  
instance, using a candidate ovarian cancer biomarker (the C-terminal fragment of the activator of the 
immunoproteasome, PA28 alpha), it is possible to detect the protein and the mRNA encoding this  
protein in the same sample. Since the result showed that the level of transcription is related to the 
abundance of the protein fragment, cross-validation between the transcriptome and the proteome can 
be performed on the same tissue. To conclude, targeted MSI associated with classical  
immunohistochemistry (IHC) may offer the possibility to obtain a quick answer and a better molecular 
diagnosis for clinical surgery [26].  
These technologies enabled the detection of low-abundance proteins, identifying hundreds of  
potential biomarkers with diagnostic, prognostic and therapeutic value. However, there is a lack of  
analytical validation of platforms for the precise measurements of the candidate markers in a smaller 
set of samples before lengthy and costly large-scale clinical trials. In this context, targeted proteomic 
technologies, such as multiplex MS, protein arrays and several variations of enzyme-linked  
immunosorbent assays (ELISAs) have provided a sensitive and specific quantitative measurement of 
protein targets in biological systems. The accuracy and statistical rigor of these technologies may be 
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used to investigate the molecular mechanism of cellular function through the analysis of protein  
networks and pathways and to confirm and triage hundreds of potential biomarkers prior to large-scale 
clinical trials. Stable isotope dilution (SID) multiple reaction monitoring MS (SID-MRMMS) has 
emerged as one of the powerful targeted proteomic tools in the past few years [27].  
4.3. Protein Microarrays 
Malignant transformation of ovarian epithelial cells is due to genetic mutations that compromise 
regulation of proliferation, differentiation and apoptosis. Since a close connection exists between  
genetic alterations and tumorigenesis, research on gene level (including inherited gene mutations,  
epigenetic changes and gene expression) could provide important biological, diagnostic and prognostic 
information. DNA or RNA-based cancer biomarkers utilize microarrays, polymerase chain reaction 
(PCR), reverse transcriptase polymerase chain reaction (RT-PCR), DNA sequencing, fluorescent  
in situ hybridization (FISH), etc., to detect the genetic alterations occurring in the cancerous state. In 
the last decade, microarray technology has allowed for the measurement of the expression of tens of 
thousands of genes in a given tissue sample and to compare gene expression between normal and  
malignant cells, identifying genes that are differentially regulated during cancer development [28]. 
Protein microarrays, similar to gene arrays, emerged as a promising technique to analyze the  
abundance of proteins and their alterations [19]. Protein microarrays are now being used to profile the 
proteome of cell populations using antigen-antibody interactions [29]. Protein microarray formats fall 
into two principal classes: forward phase arrays (FPA) and reverse phase arrays (RPAs). In forward-phase 
arrays (FPAs), antibodies are arrayed and probed with cell lysates, while in reverse-phase arrays 
(RPAs), cell lysates are arrayed and probed with antibodies [18, 30]. Contrary to FPAs, RPAs do not 
require labelling of cellular protein lysates and constitute a useful platform for biomarker screening, 
pathophysiologic studies and therapeutic monitoring. Furthermore, the RPA has a unique ability to  
analyze signaling pathways using small numbers of cultured cells or cells isolated by laser capture  
microdissection (LCM) from human tissues procured during clinical trials [30]. The major limitation 
for RPAs is the specific antibodies that are required. In ovarian cancer, the RPA platform has been 
used to study disease progression and profile signaling pathways, identify therapeutic targets and  
suggest prognostic indicators.  
5. Proteomics and Post-Translational Modifications 
Proteomic strategies are able to provide more detailed information about biological systems than 
the determination of the static genome or expression profiling based on mRNA. In contrast to the  
genome, the complexity of the proteome is increased by alternative splicing of mRNAs and a wide  
variety of post-translational events (such as glycosylation, phosphorylation and ubiquitination). For all 
these reasons, genomics and mRNA analysis do not correlate with protein content, while proteomics 
may study the presence of a specific protein and provide a measure of the quantity present. 
Glycosylation is one of the most common post-translational modifications. The mechanism of  
glycosylation is involved in several biological processes, including cell communication, adhesion and 
signaling. Moreover, the association between aberrant glycosylation and disease development has 
promoted a number of research activities directed to provide reliable diagnostic or prognostic  
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information [31]. MS glycomics methods have been successfully employed to compare the glycomic 
profiles of different samples collected from healthy individuals and ovarian cancer patients [32].  
Particularly, Abbott et al. studied the differences in the transcripts of a restricted set of  
glycosyltransferases involved in N-linked glycosylation in ovarian cancer tissues and normal ovarian 
tissues, identifying candidate biomarkers with cancer-specific glycosylation, such as periostin and 
thrombospondin [33]. More recently, Shetty et al. found that several proteins are aberrantly sialylated 
in N-linked glycopeptides in ovarian cancer tissue, and detection of glycopeptides with abnormal  
sialylation changes may be exploited as biomarkers for ovarian cancer [34]. Finally, Kuzmanov et al. 
identified the sialome (i.e., sialic acid included in glycoproteins) utilizing tandem mass spectrometry 
as a potential pool of novel biomarker candidates. In all of the samples analyzed, 579 glycosylation 
sites on 333 proteins were identified [35]. To conclude, the proteins identified through glycomics 
strategies could form the basis for future studies examining and quantifying their glycosylation status 
as biomarkers of ovarian cancer.  
Reversible protein phosphorylation represents one of the most dynamic post-translational  
modifications. Rapid changes of protein phosphorylation largely influence signaling networks, playing 
a crucial role in the regulation of many cellular processes, including metabolism, differentiation,  
migration, proliferation and apoptosis. Phosphoproteomic strategies represent the optimal choice for 
studying phosphorylation-based signaling networks. The proteomics development in the area of MS 
has been improving with the breakthrough of quantitative MS through ICAT (isotope-coded affinity 
tag), iTRAQ (Isobaric tags for relative and absolute quantitation), isobaric peptide termini labeling 
(IPTL) and SILAC (stable isotope labeling by amino acids in cell culture). SILAC, the most extensively 
used method during the past years, represents an accurate and inexpensive procedure that can be used 
as a quantitative proteomic approach in any cell culture system [36]. Phosphoproteins co-exist with 
their unphosphorylated isoform within the cell and often are present in low quantity. Thus, to improve 
the identification of phosphoprotein, removing non-phosphorylated proteins from the sample and  
enriching for the phosphorylated isoforms is necessary before MS. This task is carried out by enriching 
techniques, such as immunoprecipitation, immobilized metal affinity chromatography (IMAC),  
metal-oxide affinity chromatography (MOAC), Phos-Tag chromatography, polymer-based metal ion 
affinity capture (PolyMAC), hydroxyapatite chromatography, enrichment by chemical modification 
and phosphopeptide precipitation [37]. Particularly, phosphoproteomics has played a significant role in 
investigating molecular mechanisms that govern oncogenesis. Phosphoproteomic strategies have been 
used to identify targets of kinase inhibitors, providing useful information to study their off-target  
effects therapeutic options [38].  
6. Proteomic Biomarkers for Ovarian Cancer 
One of the main goals of proteomics is the identification of biomarkers for diseases from tissues 
and body fluids. Current diagnostic tools have had very limited success in early detection of ovarian 
cancer. The search for an ovarian cancer screening modality with improved specificity and sensitivity 
has led to the examination of serum biomarker patterns using new “omic” technologies [39–41].  
Several studies have analyzed the proteomic profiles of ovarian tumor tissue, cell lines, urine, ascites 
fluid and blood samples from ovarian cancer patients (Table 2) [42–46].  
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Table 2. Promising biomarkers discovered by proteomic technology for ovarian cancer diagnosis. 
Authors Identified biomarkers Regulation in cancer 
Cortesi et al. (2011) [42] 
Annexin-5 (ANXA5) ↓ 
Phosphatidylethanolamine-binding protein 1 (PEBP) ↓ 
Glutathione S-transferase A2 (GSTA2) ↓ 
Galectin-3 (LEG3) ↓ 
Protein S100-A8-calgranulin A (S100A8) ↑ 
Retinol binding protein (RET1) ↓ 
Petri et al. (2009) [43] 
Fibrinogen alpha fragment ↑ 
Collagen alpha 1 (III) fragment ↑ 
Fibrinogen beta NT fragment ↑ 
Li et al. (2009) [44] 
Pyridoxine II ↓ 
Pyridoxine-III ↑ 
Heat shock protein 27 (HSP27) ↑ 
Heat shock protein 60 (HSP60) ↑ 
Mitochondrial short-chain enoyl-CoA hydratase ↑ 
Prohibitin ↑ 
Jackson et al. (2007) [45] Vitamin E-binding plasma protein, Afamin ↓ 
An et al. (2006) [46] 
Annexin-1 (ANXA1) ↑ 
NM23-H1 ↑ 
Protein phosphatase-1 ↑ 
Ferritin light chain ↑ 
Proteasome alpha-6 ↑ 
N-acetyl glucosamine kinase (NAGK) ↑ 
A recent comparative proteomic study investigated and defined protein expression patterns  
associated with advanced stage ovarian cancer, to identify a panel of diagnostic or prognostic markers. 
The study also investigated proteins secreted by the cancer cell into the interstitial fluid, as cancer 
growth and progression also depends on stromal factors present in the tumor microenvironment. 
Moreover, many biomarkers present in biopsied cancer tissues can also be found in blood serum,  
representing potential biomarkers of the disease. Proteomic profiling of differentially expressed  
proteins in cancer ovarian tissue, tumoral interstitial fluid (TIF) and ascitic fluid, compared with 
healthy tissue sample and normal interstitial fluid (NIF), allowed for the identification of protein spots 
consistently differentially expressed between normal and cancer samples (Figures 3 and 4). 
Protein expression/identification was evaluated by 2DE (two-dimensional gel electrophoresis) and 
MS (mass spectrometry) analysis and were confirmed by immunohistochemistry. Six proteins showed 
differential expression in tumoral interstitial fluid and tumor tissue compared to normal interstitial  
fluid and healthy tissue. Protein different expression between tumoral and normal ovarian tissue is  
presented in Table 3. 
Five were found to be downregulated and identified as galectin 3, glutathione S-transferase A-2, 
retinol binding protein 1, phosphatidylethanolamine-binding protein and annexin 5, while the  
calgranulin was significantly upregulated in all pathological samples, including the ascitic fluid. This 
is the first study to report an overexpression of calgranulin by 2DE associated with MS/MS analysis on 
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surgical biopsy. As previously reported, the reduced expression of galectin 3 and retinol binding  
protein 1 in cystic fluid and serum of patients with early stage disease is confirmed in this study. The 
results highlight alterations in proteins that control cell-cycle progression and apoptosis, as well as  
factors that modulate the activity of signal transduction pathways [42]. 
Figure 3. Comparison between proteome of normal ovarian tissue and the corresponding 
tumor tissue. Representative gels derived from normal ovarian tissue (A and B) and  
ovarian cancer tissue (C and D) of a single patient. A total of seven differentially expressed 
protein spots in tumor tissue are annotated and identified by mass spectrometry  
(MS) analysis. 
 
Figure 4. Comparison between proteins secreted by ovarian normal interstitial fluid (NIF) 
and by ovarian tumoral interstitial fluid (TIF). Two-dimensional gel electrophoresis (2DE) 
images of protein in NIF (panel A), obtained from healthy ovarian tissue biopsies and in 
TIF (panel B), obtained from ovarian cancer biopsies. Molecular weight (kDa) and  
isoelectric values (pI) are shown on the image. Arrows indicate proteins differentially  
expressed and identified by MS analysis. 
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Table 3. Modification in protein expression in tissue and interstitial fluid. 
Protein FOLD CHANGE *  
tumoral vs. normal tissue 
p-value FOLD CHANGE *  
TIF vs. NIF 
p-value 
ANXA5 −1.88 ± 0.48 <0.0001 −5.605 ± 3.29 <0.01 
PEBP −4.21 ± 2.90 <0.01 −2.82 ± 0.69 <0.0001 
GSTA2 −4.67 ± 1.88 <0.0001 −27.39 ± 21.24 <0.01 
LEG3 −2.19 ± 0.69 <0.0001 −5.10 ± 4.42 <0.05 
S100A8 3.67 ± 1.50 <0.01 3.58 ± 1.11 <0.0001 
RET1 −6.33 ± 3.30 <0.001 −5.01 ± 4.28 <0.05 
* The fold change indicates the direction and the magnitude of the change in expression level. Data are  
expressed as the mean ± standard deviation. 
Petri et al. [43] examined whether urine could be used to measure specific ovarian cancer proteomic 
profiles and whether one peak alone or in combination with other peaks or CA125 had the sensitivity 
and specificity to discriminate between ovarian cancer pelvic mass and benign pelvic mass.  
Twenty-one significantly different peaks (p < 0.001) were visualized, and the three most significant 
peaks were identified as the fibrinogen alpha fragment, collagen alpha 1 (III) fragment and fibrinogen 
beta NT fragment. These results supported the feasibility of using urine as a diagnostic tool and  
suggested the enhanced prediction performance of combined marker analysis.  
Li et al. [44] performed a comparative proteomic study of normal ovarian epithelial and ovarian  
epithelial serous cystadenocarcinoma tissue and identified six proteins significantly differentially  
expressed. Particularly, Prx-II expression was found linearly decreased from normal ovarian tissue, 
benign ovarian lesions and to ovarian malignancies. No statistically difference between carcinomas 
groups in different clinical stage, differentiation status and histological type was seen, suggesting that 
the decrease level of prx-II is a common marker for ovarian malignancies. This represented the first 
report on the altered expression of prx-II in ovarian cancer.  
Jackson et al. [45] identified the vitamin E-binding plasma protein, Afamin, as a potential novel  
tumor marker, using proteomic-based approaches. This protein, found decreased in patients with  
ovarian cancer, was then analyzed in a large case-control study to evaluate the diagnostic utility. The 
study indicated that Afamin alone is not sufficiently suitable as a diagnostic marker, but can increase 
the Ca 125 sensitivity a little [47]. Recently, the prognostic value of Afamin, alone and in combination 
with Ca 125 has been evaluated in serum samples of patients with first diagnosis of primary ovarian 
cancer. Afamin, measured before surgery and after platinum-based chemotherapy, showed no  
correlation with any considered parameters, such as FIGO stage, residual post-operative tumor, 
platinum sensitivity, histological subtype, grade and age [48].  
An et al. [46] identified that different histologic subtypes of ovarian malignant epithelial tumors 
showed distinctively different protein expression profiles. The potential candidate biomarkers screened 
in ovarian tumors found to be significantly upregulated in comparison to normal tissues were: protein 
phosphatase-1, ferritin light chain, proteasome R-6 and NAGK (N-acetylglucosamine kinase).  
In 2008, the FDA approved human epididymis protein 4 (HE4) to monitor recurrence or progression of 
epithelial ovarian cancer. Moreover, reliable clinical evidence demonstrates that HE4, alone or in 
combination with CA125, improves the accuracy of screening [49]. HE4 is a secreted glycoprotein 
overexpressed by serous and endometrioid ovarian cancers and expressed by 32% of ovarian cancers 
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with non-elevated CA125 [50]. The analysis of this protein represents a valuable tool for ovarian  
cancer diagnosis, but, when combined with CA125, the marker acquires a higher sensitivity, providing 
a more accurate predictor of ovarian cancer than alone [51]. Notably, Moore et al. published a series of 
papers that used a combination of CA125, HE4 and menopausal status to predict the presence of a  
malignant ovarian tumor and developed the Risk of Ovarian Malignancy Algorithm (ROMA), a simple 
biomarker-based algorithm, which requires ultrasound [52,53]. 
Since ovarian cancer represents a complex and heterogeneous disorder, it is unlikely that a single 
biomarker could be able to discriminate between healthy women and patients with ovarian cancer. The 
use of a combination of biomarker candidates could provide higher specificity and sensitivity for early 
detection of ovarian cancer [54,55]. On this basis, several novel multiplex assays that use  
combinations of different biomarkers have been developed. The combination of leptin, prolactin,  
osteopontin, insulin-like growth factor II, macrophage inhibitory factor and CA 125 yielded 95.3% of 
sensitivity and 99.4% of specificity, providing a potential useful alternative to screening with CA 125 
alone for the diagnosis of ovarian cancer [56]. Different combinations of HE4, mesothelin, CEA,  
VCAM-1, B7-H4 and YKL-40 in association with CA 125 are under study for early detection. Other 
promising biomarkers include KLK6/7, GSTT1, prostasin (PRSS8), FOLR1 and ALDH1 [57].  
Moreover, a combination of human cationic antimicrobial protein-18 (hCAP-18), Lactoferrin and 
CD163 has been analyzed in normal healthy women and ovarian cancer patients, finding a multivariate 
index assay with significantly increased diagnostic efficiency. The biomarker panel is worthy of  
further investigation in a larger phase 2 trial [58]. However, several questions about the current  
paradigm for biomarker development still remain open. If markers discovered in diagnostic samples 
are differentially expressed only when the tumor becomes large, it is possible that such markers may 
have little value for early detection. In this regard, Moore et al. evaluated several biomarkers alone and 
in combination with CA 125 in prediagnostically collected sera from women in the Prostate, Lung, 
Colorectal and Ovarian Cancer Screening trial. In contrast to the prior findings on post-diagnostically 
collected samples, the addition of these biomarkers to CA125 did not improve sensitivity for preclinical 
diagnosis [59]. In addition to this study, five other panels were evaluated, none of which improved  
upon results with CA125 alone. Zhang et al. created a large scale database of 1129 proteins,  
combining information from ovarian cancer tissues and normal tissues, to enable tumor marker  
discovery [60]. In 2007, Polanski and Anderson found that out of the 1261 proteins believed to be  
differentially expressed in human cancer, only nine have been approved as “tumor associated antigens” 
by the Food and Drug Administration (FDA) [61]. Despite the wide abundance of reported  
candidate-biomarkers in the literature, only a few proteins are then verified and validated for clinical use. 
The reasons of this lack of correspondence between laboratory data and clinical setting lies in the  
inability of current technologies to significantly verify the presence of the promising biomarkers in  
patient samples and the failure to identify proteins with high specificity for a particular disease.  
In 2009, the FDA cleared the OVA1 test to assess preoperatively the risk of ovarian cancer among 
women with known pelvic masses. The test represents a useful tool to assist physicians in determining 
which patient would benefit from referral to a specialist surgeon, who would be able to perform 
debulking and staging surgeries that form the basis of optimal care for ovarian cancer. The OVA1 test 
is an in Vitro Diagnostic Multivariate Index Assay (IVDMIA) of the following five proteomic biomarkers: 
CA125, transthyretin (prealbumin), apolipoprotein A1, beta 2 microglobulin and transferrin. These  
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biomarkers, other than CA125, were part of seven biomarkers measured by SELDI MS analysis in  
serum specimens from multiple centers [62,63]. Unfortunately, the reproducibility of the SELDI assay 
was not adequate for the routine clinical use; thus, only four proteomic biomarkers measured by  
immunoassay in addition to CA 125 were selected for the validation of the immunoassay-based OVA1 
test. Proteomic profiling by mass spectrometry may not be adequate as diagnostic tool, but the profiles 
that differentiate tumoral tissue from normal tissue may help to identify the proteins candidate as  
potential biomarkers [64,65]. 
To conclude, critical assessment of the results has shown significant shortcomings and uncertainties 
in regard to the reproducibility of the findings and identity of the proteins behind the pattern peaks; 
thus, the validation of the newly discovered biomarkers still remains the most challenging aspect of 
clinical proteomics, whereas utilizing pre-diagnostic samples for discovery may be helpful in developing 
validated early detection panels [66].  
7. Proteomic Profiling for Targeted Therapies 
Proteomic technologies may help to analyze protein signaling pathways to define the preferred  
targets of patient-tailored molecular therapy. Assessing quantity and functionality of proteins, taking 
into account the genetic, epigenetic and proteomic features of ovarian cancer cells, may guide  
treatment decisions. Target therapies may be effective for the subset of patient who harbor tumors with  
specific protein network defects; thus, the proteomic approach may help to select patients who truly 
benefit from select molecular therapy.  
Posadas et al. examined epidermal growth factor receptor (EGFR) and downstream pathways in a 
phase II clinical trial of gefitinib in ovarian cancer. Notably, the author observed a lack of association 
between biochemical and clinical effects, since a decrease in the quantity of both total and  
phosphorylated EGFR in tumor tissue with the administration of gefitinib was not associated with a 
clinical benefit [67]. Even c-KIT and the platelet-derived growth factor receptor (PDGFR) have been 
studied as potential molecular target in ovarian cancer [68], and several other trials with  
proteomic endpoints are still ongoing [4]. 
Maloney et al. found protein expression changes in ovarian cancer cells in response to HSP90  
inhibitor 17AAG [69]. The histone deacetylase inhibitor, thiol-specific antioxidant (TSA), was shown 
to increase acetylation by 30% above control levels. Of note, when 17AAG was added together with 
TSA to ovarian cancer cells, a significant decrease in acetylation was observed compared with both the 
untreated control and TSA alone-treated cells. Combination studies of TSA with 17AAG gave a  
combination index of 2.92 ± 0.64 (SD, n = 3). These results showed that acetylation levels are altered 
following HSP90 inhibition, suggesting that effects on protein acetylation may potentially play a role 
in the mechanism of action of HSP90 inhibitors. They also suggested that care should be taken in 
combining histone deacetylase and HSP90 inhibitors to decrease cell proliferation. 
Genetic aberrations in BRCA 1/2 genes are the best validated genetic molecular target in ovarian 
cancer. The poly (ADP-ribose) polymerase (PARP) inhibitors represent a considerable promise for the 
treatment of cancers in BRCA 1/2 mutation carriers. This therapeutic approach exploits a synthetic  
lethal strategy to target the specific DNA repair pathway in these tumors [70]. Particularly, in recent 
clinical trials, BRCA mutations carriers showed favorable responses to the PARP inhibitor olaparib 
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compared with patients without BRCA mutations [71]. Interestingly, Stefansson et al. showed that  
the development of a subset of sporadic tumors is similar in genomic alterations to that of  
BRCA1/2-related tumors. The importance of these observations lies in the potential benefit from  
targeted therapy, through the use of PARP inhibitors, for a much larger group of patients than the 
BRCA1/2 germline mutation carriers [72]. 
However, despite the good premises, this wealth of information has yielded little in changing the 
clinical care from a treatment perspective [4]. 
8. Conclusions 
Ovarian cancer represents one of the four main gynecological tumors with an increasing  
incidence and the poorest survival of all gynecological cancer sites. In the last few decades, new  
approaches at the molecular and cellular level have given useful insights to improve early detection 
and to personalize treatment strategies. Ovarian cancer represents a heterogeneous disorder with  
different epidemiology, precursor lesions, gene expression profiles, biomarkers, therapy responses and  
prognosis, according to each distinct histotype. In order to identify a gene-proteomic signature that 
may bring to the definition of specific profiles, gene and protein expression analyses have been widely  
introduced. Particularly, the development and implementation of advanced investigation technologies 
lead to a substantial change of research objectives toward a genetic and proteomic setting. 
Proteomic techniques characterize all proteins in a biological system. One of the main goals of  
proteomics is the identification of biomarkers for diseases from tissues and body fluids. The advancing 
techniques for proteomics have shown promise in a variety of studies identifying several potential 
candidate biomarkers and prognostic indicators of outcome and response to therapy, but few have 
turned out to be useful in the clinical setting. The use of a combination of biomarkers may  
improve specificity and sensitivity for early detection of ovarian cancer. Thus, in the last few years, 
several multiplex assays integrating different candidate biomarkers, sometimes associated with  
radiological and clinical features, have been developed (such as ROMA). However, a number of  
questions about the current paradigm for biomarker development in the diagnostic setting still remain 
open, and in future research, utilizing pre-diagnostic samples for discovery may be necessary to  
develop validated early detection panels. Despite the wide abundance of candidate-biomarkers, only a 
few proteins have been validated for clinical use by the FDA. Among these, HE4 has been approved to 
monitor recurrence or progression of epithelial ovarian cancer, and the OVA-1 test has been cleared to 
assess preoperatively the risk of ovarian cancer among women with known pelvic masses. At present, 
the development of an effective strategy for early detection of ovarian cancer is still a work in  
progress. On the other hand, proteomics have given useful insight into the perturbations of signaling 
pathways within tumor cells, allowing for the discovery of new drug targets and helping to select  
patients who truly benefit from select molecular therapy. However, this wealth of information has 
yielded little in changing clinical care from a treatment perspective.  
In conclusion, parallel to the increasing optimism for proteomic expression profiling, an increasing 
need for accurate and rigorous research is required to answer clinically relevant questions, since,  
to date, integrating the biochemical information into clinical management still remains an  
unresolved challenge.  
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